RICHARD S. STEIN, M.D.; HARVEY M. GOLOMB, M.D.; CHARLES H. DIGGS, M.D.; PETER MAUCH, M.D.; SAMUEL HELLMAN, M.D.; PETER H. WIERNIK, M.D.; JOHN E. ULTMANN, M.D.; DAVID S. ROSENTHAL, M.D.
The clinical significance of anatomic substage was assessed in 130 patients with Hodgkin's disease in pathologic stage III-A: stage III-A includes involvement of spleen, or splenic, celiac, or portal nodes, or any combination of these; stage III-A includes involvement of para-aortic, iliac, or mesenteric nodes, with or without upper abdominal involvement. Median follow-up was 58 months. Both 5-year disease-free survival, 74% versus 46%, and 5-year survival, 94% versus 65%, were better (P < 0.001) in stage III-A than in stage III2-A. In stage III,-A, 5-year disease-free survival was better in patients receiving radiotherapy and chemotherapy than in patients receiving radiotherapy alone as initial treatment, 96% versus 63%, P < 0.003; however, 5-year survival rates in these treatment groups were similar, 100% versus 91%, P = 0.22. For stage III2-A, both 5-year disease-free survival, 76% versus 32%, P < 0.001, and 5-year survival, 84% versus 56%, P < 0.03, were superior with radiotherapy-chemotherapy. Consideration of anatomic substage may aid therapeutic planning for stage III Hodgkin's disease.
STEIN RS, GOLOMB HM, DIGGS CH, et al. Anatomic Substages of Stage III-A Hodgkin's Disease: A Collaborative Study. Ann Intern Med. 1980;92:159–165. doi: 10.7326/0003-4819-92-2-159
Download citation file:
Published: Ann Intern Med. 1980;92(2_Part_1):159-165.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use